Umbilical cord serum eyedrops

PreclinicalSmall molecule

Umbilical cord serum eyedrops is one of 30 small molecule programs targeting Dry Eye Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dry Eye SyndromeActive, not recruiting

Dry Eye SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

81 competitors in Dry Eye Syndrome

#DrugCompanyPhaseTrials

Alphagan

Sodium Hyaluronate

1 3

Cyclosporine a

Novartis

Phase 3

1 4

Cosentyx

Ilaris

Restasis

Aurinia Pharmaceuticals

Phase 3

6 7

Cyclosporin a

Novartis

Phase 2

1 8

NOVA22007

SSanten Inc.

Phase 3

1 9

HU007

HHuons Co., Ltd.

Phase 3

4 10

RGN-259

RReGenTree, LLC

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dry Eye Syndrome1 trial

Comparison of Autologous Serum and Umbilical Cord Serum Eyedrops for Dry Eye Syndrome

Completed·—·N/A·NCT00442273

Unspecified1 trial

Umbilical Cord Serum Eye Drops

Completed·—·N/A·NCT01016158

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Umbilical cord serum eyedrops. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Umbilical cord serum eyedrops compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Umbilical cord serum eyedrops. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chonnam National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CChonnam National University Hospital

Umbilical cord serum eyedrops

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dry Eye Syndrome1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News